A Phase 1, Open-label, Dose-escalation, Multicenter Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Activity of ADCT-301 in Patients with Relapsed or Refractory CD25-positive Acute Myeloid Leukemia or CD25-positive Acute Lymphoblastic Leukemia
The goal of this clinical research study is to find the highest tolerable dose of ADCT-301 that can be given to patients with AML or ALL. Researchers also want to learn if the study drug can affect the disease. This is the first study using ADCT-301 in patients with AML or ALL.
Treatment Location: N/A
IRB Review and Approval Date: 08/16/2016
Recruitment Status: Closed
Projected Accrual: N/A
Information and next steps
For general questions about clinical trials: